News 2026-09-01
Porton to Showcase End-to-End CDMO Expertise at CPHI Milan 2026
CPHI Milan, the world's premier pharmaceutical trade show, will take place from October 6–8, 2026, at Fiera Milano (Rho), Milan, Italy. As the most influential flagship event in the global pharmaceutical and manufacturing industry, CPHI Milan 2026 is expected to gather over 62,000 attendees, 2,400+ exhibiting companies, and 180+ speakers from more than 166 countries. CPHI creates connections and inspires partnerships across the global pharma community, championing innovation at the heart of pharma through in-person and online events that grant access to endless opportunities.

Porton Pharma Solutions will proudly showcase its integrated CDMO capabilities at Booth 10K6. As an End-to-End CDMO companies, Porton will present its customized R&D and GMP manufacturing services to pharmaceutical and biotech clients, as well as research institutions worldwide, spanning the entire drug lifecycle from preclinical development to commercialization. Our capabilities cover both drug substances and drug products across multiple modalities, including Small Molecules, TIDES, Biologics and Conjugates (ADCs, AOCs, DACs, PDCs, RDCs, etc.), and Advanced Therapy Medicinal Products. As of June 30, 2026, Porton had over 4,400 employees globally, built partnerships with more than 1,500 customers, and successfully delivered approximately 6,000 projects. Porton is committed to empowering global clients with efficient, high-quality custom R&D and manufacturing solutions, facilitating seamless translation from preclinical research to commercial launch.
At this year's event, our scientists and global business development team will be on-site to engage with industry leaders, explore the latest trends and developments in pharmaceuticals, and co-create the future of drug innovation.
For onsite meeting appointments, please contact us via:
-
Visit the offline meeting section on Porton's official website
-
Email: business@portonpharma.com
Others
More
News 2026-10-22
Simplifying Synthesis with Radical Cross-Coupling: Prof. Phil S. Baran of Scripps Research Lectures at Porton
The event was hosted by Dr. Yongli Zhong, CSO, and attended by Mr. Oliver Ju, Chairman and CEO; Mr. Yunxing Yin, VP and Head of the Small Molecule Platform, and more than 200 R&D and technical staff.

News 2026-10-16
Porton Achieves Third-Party Verification for Its First Commercial Product LCA and PCF Study
Conducted in accordance with ISO 14040:2006 and ISO 14044:2006 (Life Cycle Assessment) and ISO 14067:2018 (Product Carbon Footprint) standards, the study employs a cradle-to-gate system boundary, marking the formal extension of Porton's ESG management from the organizational level to the product level.